[
  {
    "ts": null,
    "headline": "Jefferies Reaffirms Merck (MRK) ‘Buy’ Rating on Gardasil Dosing Stability",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is another biopharmaceutical company on the list of the 10 undervalued blue chip stocks analysts recommend for smart investing. On June 18, Jefferies analyst Akash Tewari maintained a “Buy” rating on the company. The associated price target for Merck & Co. stock remains at $138.00. According to the analyst, the […]",
    "url": "https://finnhub.io/api/news?id=c2bd15d38f0839355b6936f8a305058e55b6e25808903fe36159af311d09a8d6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750800109,
      "headline": "Jefferies Reaffirms Merck (MRK) ‘Buy’ Rating on Gardasil Dosing Stability",
      "id": 135515152,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is another biopharmaceutical company on the list of the 10 undervalued blue chip stocks analysts recommend for smart investing. On June 18, Jefferies analyst Akash Tewari maintained a “Buy” rating on the company. The associated price target for Merck & Co. stock remains at $138.00. According to the analyst, the […]",
      "url": "https://finnhub.io/api/news?id=c2bd15d38f0839355b6936f8a305058e55b6e25808903fe36159af311d09a8d6"
    }
  },
  {
    "ts": null,
    "headline": "MRK's Winrevair Phase III Study in Newly Diagnosed PAH Meets Goal",
    "summary": "Merck's Winrevair meets goal in a phase III study in newly diagnosed PAH patients, showing strong efficacy.",
    "url": "https://finnhub.io/api/news?id=ffef75392d5f3cc01f3cab272e4aac23f379d5a91e27ee6aae3a81202292688b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750782000,
      "headline": "MRK's Winrevair Phase III Study in Newly Diagnosed PAH Meets Goal",
      "id": 135515153,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck's Winrevair meets goal in a phase III study in newly diagnosed PAH patients, showing strong efficacy.",
      "url": "https://finnhub.io/api/news?id=ffef75392d5f3cc01f3cab272e4aac23f379d5a91e27ee6aae3a81202292688b"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer to Face Several Headwinds: Can It Successfully Navigate Them?",
    "summary": "PFE faces a decline in COVID revenues, LOE pressure and IRA impacts but rising EPS estimates offer a glimmer of resilience.",
    "url": "https://finnhub.io/api/news?id=5c4f7360a1b1e638f10f9ab708d3565e404a83552a33b49e9cbfe943a62a8e22",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750775100,
      "headline": "Pfizer to Face Several Headwinds: Can It Successfully Navigate Them?",
      "id": 135506341,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "PFE faces a decline in COVID revenues, LOE pressure and IRA impacts but rising EPS estimates offer a glimmer of resilience.",
      "url": "https://finnhub.io/api/news?id=5c4f7360a1b1e638f10f9ab708d3565e404a83552a33b49e9cbfe943a62a8e22"
    }
  },
  {
    "ts": null,
    "headline": "Sanofi Trades Below 50 & 200-Day Moving Averages: Time to Buy the Dip?",
    "summary": "SNY trades below key moving averages but strong Dupixent growth, pipeline wins and rising estimates may keep bulls invested.",
    "url": "https://finnhub.io/api/news?id=4f1814c61898f002612a3f6e6c7351d3491b9154d4a45ccd53d735bc987373e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750773360,
      "headline": "Sanofi Trades Below 50 & 200-Day Moving Averages: Time to Buy the Dip?",
      "id": 135506743,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "SNY trades below key moving averages but strong Dupixent growth, pipeline wins and rising estimates may keep bulls invested.",
      "url": "https://finnhub.io/api/news?id=4f1814c61898f002612a3f6e6c7351d3491b9154d4a45ccd53d735bc987373e0"
    }
  },
  {
    "ts": null,
    "headline": "EXEL Stock Rises on Positive Data From Colorectal Cancer Study",
    "summary": "EXEL jumps 7.4% as STELLAR-303 trial hits key survival goal in colorectal cancer, boosting hopes for an approval of zanzalintinib.",
    "url": "https://finnhub.io/api/news?id=ec78ab15a54176d6f3131d16a7c6fd081afeece1ff982674fbe2a511f3eeb434",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750772400,
      "headline": "EXEL Stock Rises on Positive Data From Colorectal Cancer Study",
      "id": 135503055,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "EXEL jumps 7.4% as STELLAR-303 trial hits key survival goal in colorectal cancer, boosting hopes for an approval of zanzalintinib.",
      "url": "https://finnhub.io/api/news?id=ec78ab15a54176d6f3131d16a7c6fd081afeece1ff982674fbe2a511f3eeb434"
    }
  },
  {
    "ts": null,
    "headline": "US CDC's report shows no evidence linking thimerosal-containing vaccines and autism",
    "summary": "The U.S. Centers for Disease Controland Prevention in a report said that evidence does not support alink between thimerosal-containing vaccines and autism. The report, along with other...",
    "url": "https://finnhub.io/api/news?id=0a5ff254c46483b780783508eb4b4ddf71b78dea9ff3059752ebfa0bbb58d8ae",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750764548,
      "headline": "US CDC's report shows no evidence linking thimerosal-containing vaccines and autism",
      "id": 135504127,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "The U.S. Centers for Disease Controland Prevention in a report said that evidence does not support alink between thimerosal-containing vaccines and autism. The report, along with other...",
      "url": "https://finnhub.io/api/news?id=0a5ff254c46483b780783508eb4b4ddf71b78dea9ff3059752ebfa0bbb58d8ae"
    }
  },
  {
    "ts": null,
    "headline": "NeoGenomics Appoints Dr. Marjorie Green to Board of Directors",
    "summary": "FORT MYERS, Fla., June 24, 2025--NeoGenomics announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025.",
    "url": "https://finnhub.io/api/news?id=32e045b65c12c13ed35c49c655e01f3b04cec0b3cc26dac5b55fdb1e95519080",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750763100,
      "headline": "NeoGenomics Appoints Dr. Marjorie Green to Board of Directors",
      "id": 135506446,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "FORT MYERS, Fla., June 24, 2025--NeoGenomics announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025.",
      "url": "https://finnhub.io/api/news?id=32e045b65c12c13ed35c49c655e01f3b04cec0b3cc26dac5b55fdb1e95519080"
    }
  },
  {
    "ts": null,
    "headline": "Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention",
    "summary": "RAHWAY, N.J., June 24, 2025--Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention",
    "url": "https://finnhub.io/api/news?id=fdfb50ac142340e5d1b04d047a2032e6e7f82590643f076917621a1167eed650",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750761900,
      "headline": "Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention",
      "id": 135506447,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., June 24, 2025--Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention",
      "url": "https://finnhub.io/api/news?id=fdfb50ac142340e5d1b04d047a2032e6e7f82590643f076917621a1167eed650"
    }
  },
  {
    "ts": null,
    "headline": "Brain Cancer Market Research Report 2025-2035 | Growing Shifts Toward Targeted Therapies and Immunotherapy Over Traditional Methods",
    "summary": "The global brain cancer treatment market is rapidly evolving, driven by the increasing incidence of brain cancer and advancements in medical technology focusing on personalized medicine. With immunotherapies and genetically tailored treatments gaining traction, the market is shifting from traditional methods to more targeted solutions. The discovery of genetic markers facilitates precision medicine strategies, marking significant milestones with new biologics and therapies. North America leads,",
    "url": "https://finnhub.io/api/news?id=afdb23ee6106154d1861a0fca4556484d5e3341b616ac43379e303f880ca6343",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750759980,
      "headline": "Brain Cancer Market Research Report 2025-2035 | Growing Shifts Toward Targeted Therapies and Immunotherapy Over Traditional Methods",
      "id": 135506448,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The global brain cancer treatment market is rapidly evolving, driven by the increasing incidence of brain cancer and advancements in medical technology focusing on personalized medicine. With immunotherapies and genetically tailored treatments gaining traction, the market is shifting from traditional methods to more targeted solutions. The discovery of genetic markers facilitates precision medicine strategies, marking significant milestones with new biologics and therapies. North America leads,",
      "url": "https://finnhub.io/api/news?id=afdb23ee6106154d1861a0fca4556484d5e3341b616ac43379e303f880ca6343"
    }
  },
  {
    "ts": null,
    "headline": "Allergic Rhinitis Market Report 2025-2035 | Innovative Drug Classes and Regional Trends Propel Expansion",
    "summary": "The global allergic rhinitis market is poised for substantial growth from 2025 to 2035, driven by a rise in allergic diseases, and advancements in therapies. Environmental changes and urbanization are escalating allergic case prevalence, emphasizing the need for effective management. Key treatment options include antihistamines, corticosteroids, and immunotherapy, tailored increasingly through personalized medicine. North America leads market share due to high healthcare expenditure and innovati",
    "url": "https://finnhub.io/api/news?id=3457d2899885c81a12b3988389fc80c0f8a1226f321f01be39716570b34839d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750759320,
      "headline": "Allergic Rhinitis Market Report 2025-2035 | Innovative Drug Classes and Regional Trends Propel Expansion",
      "id": 135505403,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The global allergic rhinitis market is poised for substantial growth from 2025 to 2035, driven by a rise in allergic diseases, and advancements in therapies. Environmental changes and urbanization are escalating allergic case prevalence, emphasizing the need for effective management. Key treatment options include antihistamines, corticosteroids, and immunotherapy, tailored increasingly through personalized medicine. North America leads market share due to high healthcare expenditure and innovati",
      "url": "https://finnhub.io/api/news?id=3457d2899885c81a12b3988389fc80c0f8a1226f321f01be39716570b34839d0"
    }
  },
  {
    "ts": null,
    "headline": "Merck Poised to Deliver Strong Results and Steady Dividend Growth",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the Best Dividend Leaders to Buy Now. Merck & Co., Inc. (NYSE:MRK) has struggled over the past year, with its stock falling nearly 40%, partly due to concerns about rising competition from therapies still in development, such as Summit Therapeutics’ ivonescimab. However, the company is working on […]",
    "url": "https://finnhub.io/api/news?id=bff7a566ad65160c4e710a15b44c3e6b62b7ff80c23d3abae5bbc2b8890fb57e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750733160,
      "headline": "Merck Poised to Deliver Strong Results and Steady Dividend Growth",
      "id": 135491021,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the Best Dividend Leaders to Buy Now. Merck & Co., Inc. (NYSE:MRK) has struggled over the past year, with its stock falling nearly 40%, partly due to concerns about rising competition from therapies still in development, such as Summit Therapeutics’ ivonescimab. However, the company is working on […]",
      "url": "https://finnhub.io/api/news?id=bff7a566ad65160c4e710a15b44c3e6b62b7ff80c23d3abae5bbc2b8890fb57e"
    }
  }
]